Syndax's Revumenib Shows Positive Phase II Results in AML

Key Insights

• Syndax Pharmaceuticals announced positive top-line results from the pivotal Phase II portion of the Augment-101 study, evaluating revumenib in acute myeloid leukemia (AML).
• The Augment-101 study is designed to assess the safety and efficacy of oral small-molecule revumenib in patients with relapsed or refractory AML.
• Despite the positive results, Syndax's shares experienced a significant drop, closing down 26% after the data release, reflecting market caution.

Syndax Pharmaceuticals Inc. has released positive top-line results from the pivotal phase II portion of the Augment-101 study, which is evaluating the oral small-molecule revumenib for safety and efficacy in relapsed or refractory acute myeloid leukemia (AML). The announcement was made public, however, shares of Syndax (NASDAQ:SNDX) closed at $16.21, a 26% decrease.

The Augment-101 study is specifically designed to test the effectiveness and safety of revumenib, an oral small-molecule drug. Revumenib is a menin inhibitor. The competitive landscape for menin inhibitors is evolving, and Syndax's data contributes to the growing body of evidence in this therapeutic area.